SV

Street Verdict

Analyst Scorecard

AGARWALEYE · NSE

Dr. Agarwal's Health Care Limited

₹553.4

+0.05% (+₹0.3)

Prev. close

₹553.1

Volume

86,094

Delivery %

51.8%

As of

20 Nov 2026

Price history

₹553.4+₹50.8 (+10.11%) · 3M
18 Aug 2026 → 20 Nov 2026
48050052054018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

No analyst stances in this range

0 analyst stances · last 90 days · one per analyst

Try a wider range.

Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions
Market commentary · 1 · levels, conditionals, previews, macro & hedged views — context, not graded
CallAnalystInstrumentVerdictActions

Fundamentals

About Dr. Agarwal's Health Care Limited

Dr. Agarwal's Health Care Limited engages in running, owning, and managing eye care hospitals, opticals, pharmacies, etc. and related services in India and internationally. It offers femto cataracts, lenticular procedure, retinal surgeries, anterior segment reconstruction, and corneal transplants, as well as refractive and other surgeries. The company also develops, designs, manufactures, imports, and exports healthcare devices, which include ophthalmic diagnostic devices, such as auto perimeter, optical biometers, and ophthalmoscopes. In addition, the company offers consultations, diagnoses, and non-surgical treatments; and sells opticals, contact lenses and accessories, and eye care related pharmaceutical products. Dr. Agarwal's Health Care Limited was incorporated in 2010 and is based in Chennai, India.

Details

Sector

Healthcare

Industry

Medical Instruments & Supplies

CEO

Dr. Adil Agarwal M.B.B.S, M.S, MBA

Headquarters

Chennai

Key stats

Market cap

₹16,448.26 Cr

P/E ratio (TTM)

111.6

Dividend yield

0.00%

EPS (TTM)

₹4.65

Beta (1Y · daily vs NIFTY 50)

0.30

Shares float

12.12 Cr

EPS · quarter ended Jun 2026

₹1.42

Financial Performance

01 · Financials

-2000 Cr0 Cr2000 Cr4000 Cr₹0%2.5%5%7.5%10%FY21FY22FY23FY24FY25FY26
RevenueNet incomeNet income ÷ revenue

EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures. Net income ÷ revenue is not drawn for FY21 and FY22 (revenue was nil or not reported).

02 · Earnings Per Share (EPS)

0246₹FY23FY24FY25FY26

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

0%25%50%75%100%FY21FY22FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

0 Cr1000 Cr2000 Cr3000 Cr4000 Cr₹0×0.5×1×1.5×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr1000 Cr2000 Cr3000 Cr4000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

-1000 Cr0 Cr1000 Cr2000 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

Cash for FY25: the figure the company printed, which its own totals confirm and the series' figure did not.

08 · Profit & Loss — as filed

Annual

Line itemFY24FY25FY26
₹1,376.45 Cr₹1,757.02 Cr₹2,124.52 Cr
₹1,235.88 Cr₹1,594.15 Cr₹1,877.21 Cr
Profit before exceptional items and Tax
₹140.57 Cr₹162.87 Cr₹247.31 Cr
a) Provision for Impairment on Goodwill
—₹3.02 Cr—
b) Fair Value Change in financial instruments
——₹-1.33 Cr
Profit before tax
₹140.57 Cr₹159.85 Cr₹248.64 Cr
₹45.52 Cr₹49.51 Cr₹80.50 Cr
₹85.54 Cr₹109.83 Cr₹185.74 Cr
Profit for the year
₹95.05 Cr₹110.34 Cr₹168.14 Cr
₹-9.51 Cr₹-51.00 L₹17.60 Cr
Owners of the company
₹83.06 Cr₹83.46 Cr₹133.19 Cr
Non controlling interests
₹11.99 Cr₹26.88 Cr₹34.95 Cr
Subtotal‡
₹95.05 Cr——
Total
—₹110.34 Cr₹168.14 Cr
Owners of the company
₹-9.53 Cr₹-56.00 L₹17.59 Cr
Non controlling interests
₹2.00 L₹5.00 L₹1.00 L
Subtotal‡
₹-9.51 Cr——
Total
—₹-51.00 L₹17.60 Cr
Owners of the company
₹73.53 Cr₹82.90 Cr₹150.78 Cr
Non controlling interests
₹12.01 Cr₹26.93 Cr₹34.96 Cr
Subtotal‡
₹85.54 Cr——
Total
—₹109.83 Cr₹185.74 Cr
Basic (in)
3.142.804.21
Diluted (in)
3.132.784.18

The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.

‡ The company printed this figure on a line with no label (a bare subtotal under a block). Where the lines above add up to it, it is named after them; otherwise it is shown as “Unlabelled line”. The figure is the company’s own.

All years: consolidated statements.

09 · Balance Sheet — as filed

Annual

Line itemFY24FY25FY26
₹2,752.82 Cr₹3,671.57 Cr₹3,941.75 Cr
₹1,994.24 Cr₹2,882.97 Cr₹3,368.78 Cr
₹758.58 Cr₹788.60 Cr₹572.97 Cr
₹1,373.31 Cr₹1,744.75 Cr₹1,822.05 Cr
₹1,339.41 Cr₹1,866.59 Cr₹2,025.46 Cr
Non controlling interest
₹40.10 Cr₹60.23 Cr₹94.24 Cr
Total equity (A)
₹1,379.51 Cr₹1,926.82 Cr₹2,119.70 Cr
₹973.51 Cr₹1,266.99 Cr₹1,360.57 Cr
₹399.80 Cr₹477.76 Cr₹461.48 Cr
Total equity and liabilities (A+B+C)
₹2,752.82 Cr₹3,671.57 Cr₹3,941.75 Cr

The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.

All years: consolidated statements.

10 · Cash Flow Statement — as filed

Annual

Line itemFY24FY25FY26
₹346.00 Cr₹357.13 Cr₹518.99 Cr
₹-913.91 Cr₹-750.33 Cr₹-308.45 Cr
₹111.75 Cr₹100.40 Cr₹90.55 Cr

The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.

All years: consolidated statements.

11 · Shareholding Pattern

NSE, quarterly

Line itemFeb 25–Mar 25(2Q)Jun 25–Sep 25(2Q)Dec 25Mar 26Jun 26
Promoter32.45%32.42%32.39%32.36%32.34%
Public67.55%67.58%67.61%67.64%67.66%
Employee trusts0.00%0.00%0.00%0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Dr. Agarwal's Health Care Limited₹16,543.38 Cr₹523.5112.08.176.6%0.53+21.9%+1.6%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.

AGARWALEYE

Dr Agarwal’s Eye Hospital Merges with Dr Agarwal’s Health Care to Unify Corporate Structure

Digital Health News · 3 days ago

AGARWALEYE

Dr Agarwal's Share Price Target 2027: Q2 Review

Univest · 4 days ago